Type 2 Diabetes

New England CEPAC

The New England CEPAC will convene to deliberate on ICER's review of oral semaglutide for the treatment of type 2 diabetes.

Key Dates

Associated Materials

04/11/2019 – 04/29/2019
Open Input Period

05/02/2019

05/02/2019

05/02/2019 – 05/22/2019

05/31/2019

07/08/2019

07/29/2019

09/11/2019

09/11/2019 – 10/08/2019

09/11/2019

11/01/2019

11/01/2019

11/01/2019

11/14/2019

11/14/2019

12/09/2019
Final Evidence Report and Meeting Summary

12/09/2019
Report-at-a-Glance